Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Oral Anti-Diabetic Drug Market

ID: MRFR/HC/40608-HCR
200 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Oral Anti-Diabetic Drug Market Research Report By Drug Class (Biguanides, Sulfonylureas, Thiazolidinediones, DPP-4 Inhibitors, SGLT2 Inhibitors), By Action Mechanism (Insulin Sensitizers, Insulin Secretagogues, Alpha-Glucosidase Inhibitors, Renal Glucose Reabsorption Inhibitors), By Prescription Type (Generic, Branded), By Patient Type (Type 1 Diabetes, Type 2 Diabetes, Prediabetes) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Oral Anti-Diabetic Drug Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS | 1.1 EXECUTIVE SUMMARY | | 1.1.1 Market Overview | | 1.1.2 Key Findings | | 1.1.3 Market Segmentation | | 1.1.4 Competitive Landscape | | 1.1.5 Challenges and Opportunities | | 1.1.6 Future Outlook 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE | 2.1 MARKET INTRODUCTION | | 2.1.1 Definition | | 2.1.2 Scope of the study | | | 2.1.2.1 Research Objective | | | 2.1.2.2 Assumption | | | 2.1.2.3 Limitations | 2.2 RESEARCH METHODOLOGY | | 2.2.1 Overview | | 2.2.2 Data Mining | | 2.2.3 Secondary Research | | 2.2.4 Primary Research | | | 2.2.4.1 Primary Interviews and Information Gathering Process | | | 2.2.4.2 Breakdown of Primary Respondents | | 2.2.5 Forecasting Model | | 2.2.6 Market Size Estimation | | | 2.2.6.1 Bottom-Up Approach | | | 2.2.6.2 Top-Down Approach | | 2.2.7 Data Triangulation | | 2.2.8 Validation 3 SECTION III: QUALITATIVE ANALYSIS | 3.1 MARKET DYNAMICS | | 3.1.1 Overview | | 3.1.2 Drivers | | 3.1.3 Restraints | | 3.1.4 Opportunities | 3.2 MARKET FACTOR ANALYSIS | | 3.2.1 Value chain Analysis | | 3.2.2 Porter's Five Forces Analysis | | | 3.2.2.1 Bargaining Power of Suppliers | | | 3.2.2.2 Bargaining Power of Buyers | | | 3.2.2.3 Threat of New Entrants | | | 3.2.2.4 Threat of Substitutes | | | 3.2.2.5 Intensity of Rivalry | | 3.2.3 COVID-19 Impact Analysis | | | 3.2.3.1 Market Impact Analysis | | | 3.2.3.2 Regional Impact | | | 3.2.3.3 Opportunity and Threat Analysis 4 SECTION IV: QUANTITATIVE ANALYSIS | 4.1 Healthcare, BY Drug Class (USD Billion) | | 4.1.1 Biguanides | | 4.1.2 Sulfonylureas | | 4.1.3 Thiazolidinediones | | 4.1.4 DPP-4 Inhibitors | | 4.1.5 SGLT2 Inhibitors | 4.2 Healthcare, BY Action Mechanism (USD Billion) | | 4.2.1 Insulin Sensitizers | | 4.2.2 Insulin Secretagogues | | 4.2.3 Alpha-Glucosidase Inhibitors | | 4.2.4 Renal Glucose Reabsorption Inhibitors | 4.3 Healthcare, BY Prescription Type (USD Billion) | | 4.3.1 Generic | | 4.3.2 Branded | 4.4 Healthcare, BY Patient Type (USD Billion) | | 4.4.1 Type 1 Diabetes | | 4.4.2 Type 2 Diabetes | | 4.4.3 Prediabetes | 4.5 Healthcare, BY Region (USD Billion) | | 4.5.1 North America | | | 4.5.1.1 US | | | 4.5.1.2 Canada | | 4.5.2 Europe | | | 4.5.2.1 Germany | | | 4.5.2.2 UK | | | 4.5.2.3 France | | | 4.5.2.4 Russia | | | 4.5.2.5 Italy | | | 4.5.2.6 Spain | | | 4.5.2.7 Rest of Europe | | 4.5.3 APAC | | | 4.5.3.1 China | | | 4.5.3.2 India | | | 4.5.3.3 Japan | | | 4.5.3.4 South Korea | | | 4.5.3.5 Malaysia | | | 4.5.3.6 Thailand | | | 4.5.3.7 Indonesia | | | 4.5.3.8 Rest of APAC | | 4.5.4 South America | | | 4.5.4.1 Brazil | | | 4.5.4.2 Mexico | | | 4.5.4.3 Argentina | | | 4.5.4.4 Rest of South America | | 4.5.5 MEA | | | 4.5.5.1 GCC Countries | | | 4.5.5.2 South Africa | | | 4.5.5.3 Rest of MEA 5 SECTION V: COMPETITIVE ANALYSIS | 5.1 Competitive Landscape | | 5.1.1 Overview | | 5.1.2 Competitive Analysis | | 5.1.3 Market share Analysis | | 5.1.4 Major Growth Strategy in the Healthcare | | 5.1.5 Competitive Benchmarking | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | | 5.1.7 Key developments and growth strategies | | | 5.1.7.1 New Product Launch/Service Deployment | | | 5.1.7.2 Merger & Acquisitions | | | 5.1.7.3 Joint Ventures | | 5.1.8 Major Players Financial Matrix | | | 5.1.8.1 Sales and Operating Income | | | 5.1.8.2 Major Players R&D Expenditure. 2023 | 5.2 Company Profiles | | 5.2.1 Novo Nordisk (DK) | | | 5.2.1.1 Financial Overview | | | 5.2.1.2 Products Offered | | | 5.2.1.3 Key Developments | | | 5.2.1.4 SWOT Analysis | | | 5.2.1.5 Key Strategies | | 5.2.2 Sanofi (FR) | | | 5.2.2.1 Financial Overview | | | 5.2.2.2 Products Offered | | | 5.2.2.3 Key Developments | | | 5.2.2.4 SWOT Analysis | | | 5.2.2.5 Key Strategies | | 5.2.3 Boehringer Ingelheim (DE) | | | 5.2.3.1 Financial Overview | | | 5.2.3.2 Products Offered | | | 5.2.3.3 Key Developments | | | 5.2.3.4 SWOT Analysis | | | 5.2.3.5 Key Strategies | | 5.2.4 Merck & Co. (US) | | | 5.2.4.1 Financial Overview | | | 5.2.4.2 Products Offered | | | 5.2.4.3 Key Developments | | | 5.2.4.4 SWOT Analysis | | | 5.2.4.5 Key Strategies | | 5.2.5 AstraZeneca (GB) | | | 5.2.5.1 Financial Overview | | | 5.2.5.2 Products Offered | | | 5.2.5.3 Key Developments | | | 5.2.5.4 SWOT Analysis | | | 5.2.5.5 Key Strategies | | 5.2.6 Johnson & Johnson (US) | | | 5.2.6.1 Financial Overview | | | 5.2.6.2 Products Offered | | | 5.2.6.3 Key Developments | | | 5.2.6.4 SWOT Analysis | | | 5.2.6.5 Key Strategies | | 5.2.7 Eli Lilly and Company (US) | | | 5.2.7.1 Financial Overview | | | 5.2.7.2 Products Offered | | | 5.2.7.3 Key Developments | | | 5.2.7.4 SWOT Analysis | | | 5.2.7.5 Key Strategies | | 5.2.8 GlaxoSmithKline (GB) | | | 5.2.8.1 Financial Overview | | | 5.2.8.2 Products Offered | | | 5.2.8.3 Key Developments | | | 5.2.8.4 SWOT Analysis | | | 5.2.8.5 Key Strategies | | 5.2.9 Takeda Pharmaceutical Company (JP) | | | 5.2.9.1 Financial Overview | | | 5.2.9.2 Products Offered | | | 5.2.9.3 Key Developments | | | 5.2.9.4 SWOT Analysis | | | 5.2.9.5 Key Strategies | 5.3 Appendix | | 5.3.1 References | | 5.3.2 Related Reports 6 LIST OF FIGURES | 6.1 MARKET SYNOPSIS | 6.2 NORTH AMERICA MARKET ANALYSIS | 6.3 US MARKET ANALYSIS BY DRUG CLASS | 6.4 US MARKET ANALYSIS BY ACTION MECHANISM | 6.5 US MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.6 US MARKET ANALYSIS BY PATIENT TYPE | 6.7 CANADA MARKET ANALYSIS BY DRUG CLASS | 6.8 CANADA MARKET ANALYSIS BY ACTION MECHANISM | 6.9 CANADA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.10 CANADA MARKET ANALYSIS BY PATIENT TYPE | 6.11 EUROPE MARKET ANALYSIS | 6.12 GERMANY MARKET ANALYSIS BY DRUG CLASS | 6.13 GERMANY MARKET ANALYSIS BY ACTION MECHANISM | 6.14 GERMANY MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.15 GERMANY MARKET ANALYSIS BY PATIENT TYPE | 6.16 UK MARKET ANALYSIS BY DRUG CLASS | 6.17 UK MARKET ANALYSIS BY ACTION MECHANISM | 6.18 UK MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.19 UK MARKET ANALYSIS BY PATIENT TYPE | 6.20 FRANCE MARKET ANALYSIS BY DRUG CLASS | 6.21 FRANCE MARKET ANALYSIS BY ACTION MECHANISM | 6.22 FRANCE MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.23 FRANCE MARKET ANALYSIS BY PATIENT TYPE | 6.24 RUSSIA MARKET ANALYSIS BY DRUG CLASS | 6.25 RUSSIA MARKET ANALYSIS BY ACTION MECHANISM | 6.26 RUSSIA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.27 RUSSIA MARKET ANALYSIS BY PATIENT TYPE | 6.28 ITALY MARKET ANALYSIS BY DRUG CLASS | 6.29 ITALY MARKET ANALYSIS BY ACTION MECHANISM | 6.30 ITALY MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.31 ITALY MARKET ANALYSIS BY PATIENT TYPE | 6.32 SPAIN MARKET ANALYSIS BY DRUG CLASS | 6.33 SPAIN MARKET ANALYSIS BY ACTION MECHANISM | 6.34 SPAIN MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.35 SPAIN MARKET ANALYSIS BY PATIENT TYPE | 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS | 6.37 REST OF EUROPE MARKET ANALYSIS BY ACTION MECHANISM | 6.38 REST OF EUROPE MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE | 6.40 APAC MARKET ANALYSIS | 6.41 CHINA MARKET ANALYSIS BY DRUG CLASS | 6.42 CHINA MARKET ANALYSIS BY ACTION MECHANISM | 6.43 CHINA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.44 CHINA MARKET ANALYSIS BY PATIENT TYPE | 6.45 INDIA MARKET ANALYSIS BY DRUG CLASS | 6.46 INDIA MARKET ANALYSIS BY ACTION MECHANISM | 6.47 INDIA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.48 INDIA MARKET ANALYSIS BY PATIENT TYPE | 6.49 JAPAN MARKET ANALYSIS BY DRUG CLASS | 6.50 JAPAN MARKET ANALYSIS BY ACTION MECHANISM | 6.51 JAPAN MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.52 JAPAN MARKET ANALYSIS BY PATIENT TYPE | 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS | 6.54 SOUTH KOREA MARKET ANALYSIS BY ACTION MECHANISM | 6.55 SOUTH KOREA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE | 6.57 MALAYSIA MARKET ANALYSIS BY DRUG CLASS | 6.58 MALAYSIA MARKET ANALYSIS BY ACTION MECHANISM | 6.59 MALAYSIA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE | 6.61 THAILAND MARKET ANALYSIS BY DRUG CLASS | 6.62 THAILAND MARKET ANALYSIS BY ACTION MECHANISM | 6.63 THAILAND MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.64 THAILAND MARKET ANALYSIS BY PATIENT TYPE | 6.65 INDONESIA MARKET ANALYSIS BY DRUG CLASS | 6.66 INDONESIA MARKET ANALYSIS BY ACTION MECHANISM | 6.67 INDONESIA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.68 INDONESIA MARKET ANALYSIS BY PATIENT TYPE | 6.69 REST OF APAC MARKET ANALYSIS BY DRUG CLASS | 6.70 REST OF APAC MARKET ANALYSIS BY ACTION MECHANISM | 6.71 REST OF APAC MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE | 6.73 SOUTH AMERICA MARKET ANALYSIS | 6.74 BRAZIL MARKET ANALYSIS BY DRUG CLASS | 6.75 BRAZIL MARKET ANALYSIS BY ACTION MECHANISM | 6.76 BRAZIL MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.77 BRAZIL MARKET ANALYSIS BY PATIENT TYPE | 6.78 MEXICO MARKET ANALYSIS BY DRUG CLASS | 6.79 MEXICO MARKET ANALYSIS BY ACTION MECHANISM | 6.80 MEXICO MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.81 MEXICO MARKET ANALYSIS BY PATIENT TYPE | 6.82 ARGENTINA MARKET ANALYSIS BY DRUG CLASS | 6.83 ARGENTINA MARKET ANALYSIS BY ACTION MECHANISM | 6.84 ARGENTINA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ACTION MECHANISM | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE | 6.90 MEA MARKET ANALYSIS | 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS | 6.92 GCC COUNTRIES MARKET ANALYSIS BY ACTION MECHANISM | 6.93 GCC COUNTRIES MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE | 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS | 6.96 SOUTH AFRICA MARKET ANALYSIS BY ACTION MECHANISM | 6.97 SOUTH AFRICA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE | 6.99 REST OF MEA MARKET ANALYSIS BY DRUG CLASS | 6.100 REST OF MEA MARKET ANALYSIS BY ACTION MECHANISM | 6.101 REST OF MEA MARKET ANALYSIS BY PRESCRIPTION TYPE | 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE | 6.103 KEY BUYING CRITERIA OF HEALTHCARE | 6.104 RESEARCH PROCESS OF MRFR | 6.105 DRO ANALYSIS OF HEALTHCARE | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE | 6.109 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) | 6.110 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) | 6.111 HEALTHCARE, BY ACTION MECHANISM, 2024 (% SHARE) | 6.112 HEALTHCARE, BY ACTION MECHANISM, 2024 TO 2035 (USD Billion) | 6.113 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 (% SHARE) | 6.114 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 TO 2035 (USD Billion) | 6.115 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE) | 6.116 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion) | 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES | 7.1 LIST OF ASSUMPTIONS | | 7.1.1 | 7.2 North America MARKET SIZE ESTIMATES; FORECAST | | 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.2.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.2.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.3 US MARKET SIZE ESTIMATES; FORECAST | | 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.3.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.3.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | | 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.4.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.4.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | | 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.5.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.5.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | | 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.6.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.6.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.7 UK MARKET SIZE ESTIMATES; FORECAST | | 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.7.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.7.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.8 France MARKET SIZE ESTIMATES; FORECAST | | 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.8.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.8.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | | 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.9.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.9.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | | 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.10.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.10.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | | 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.11.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.11.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | | 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.12.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.12.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | | 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.13.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.13.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.14 China MARKET SIZE ESTIMATES; FORECAST | | 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.14.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.14.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.15 India MARKET SIZE ESTIMATES; FORECAST | | 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.15.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.15.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | | 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.16.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.16.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | | 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.17.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.17.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | | 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.18.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.18.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | | 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.19.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.19.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | | 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.20.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.20.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | | 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.21.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.21.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.22 South America MARKET SIZE ESTIMATES; FORECAST | | 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.22.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.22.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | | 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.23.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.23.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | | 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.24.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.24.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | | 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.25.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.25.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | | 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.26.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.26.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | | 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.27.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.27.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | | 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.28.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.28.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | | 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.29.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.29.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | | 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | | 7.30.2 BY ACTION MECHANISM, 2025-2035 (USD Billion) | | 7.30.3 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) | | 7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion) | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | | 7.31.1 | 7.32 ACQUISITION/PARTNERSHIP | | 7.32.1

Healthcare Market Segmentation

Healthcare By Drug Class (USD Billion, 2025-2035)

  • Biguanides
  • Sulfonylureas
  • Thiazolidinediones
  • DPP-4 Inhibitors
  • SGLT2 Inhibitors

Healthcare By Action Mechanism (USD Billion, 2025-2035)

  • Insulin Sensitizers
  • Insulin Secretagogues
  • Alpha-Glucosidase Inhibitors
  • Renal Glucose Reabsorption Inhibitors

Healthcare By Prescription Type (USD Billion, 2025-2035)

  • Generic
  • Branded

Healthcare By Patient Type (USD Billion, 2025-2035)

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Prediabetes

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions